TY  - JOUR
AU  - Navarro, Natalia
AU  - Molist, Carla
AU  - Sansa-Girona, Julia
AU  - Zarzosa, Patricia
AU  - Gallo-Oller, Gabriel
AU  - Pons, Guillem
AU  - Magdaleno, Ainara
AU  - Guillen, Gabriela
AU  - Hladun, Raquel
AU  - Garrido, Marta
AU  - Segura, Miguel F
AU  - Hontecillas-Prieto, Lourdes
AU  - de-Alava, Enrique
AU  - Ponsati, Berta
AU  - Fernandez-Carneado, Jimena
AU  - Almazan-Moga, Ana
AU  - Valles-Miret, Mariona
AU  - Farrera-Sinfreu, Josep
AU  - Sanchez-de-Toledo, Josep 
AU  - Moreno, Lucas
AU  - Gallego, Soledad
AU  - Roma, Josep
PY  - 2022
DO  - 10.1007/s00018-022-04557-y
UR  - http://hdl.handle.net/10668/19542
T2  - Cellular and molecular life sciences : CMLS
AB  - The majority of current cancer therapies are aimed at reducing tumour growth, but there is lack of viable pharmacological options to reduce the formation of metastasis. This is a paradox, since more than 90% of cancer deaths are attributable to...
LA  - en
PB  - Birkhaeuser Science
KW  - Cancer
KW  - Dissemination
KW  - Paediatric cancer
KW  - Progression
KW  - Solid tumours
KW  - ADAM Proteins
KW  - Humans
KW  - Integrin alpha Chains
KW  - Integrins
KW  - Neoplasm Metastasis
KW  - Neuroblastoma
KW  - Rhabdomyosarcoma
TI  - Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma.
TY  - research article
VL  - 79
ER  -